Overcoming Cancer Drug Resistance with A Bispecific Inhibitor

Drug resistance presents a significant challenge to oncologists. Therapies that were once capable of destroying the tumor are rendered ineffective once one resistant cancer cell begins to multiply. Part of the challenge of developing effective cancer therapies is tackling the multiple pathways by which drug resistance arises. Isaac Israel, CEO of Kitov Pharmaceuticals, and his team are hoping to rise to this challenge. Results from recent preclinical studies suggest that their small molecule drug, NT-219, can effectively block two signaling proteins that function in two different resistance pathways.